10-Q
2024-09-30http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMembertruetruehttp://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember0001531048Q1false--12-310001531048us-gaap:EmployeeStockMember2022-01-012022-03-310001531048srt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001531048us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100015310482022-05-310001531048us-gaap:TechnologyEquipmentMember2022-03-310001531048us-gaap:CashAndCashEquivalentsMember2022-03-310001531048us-gaap:RetainedEarningsMember2021-03-310001531048us-gaap:LondonInterbankOfferedRateLIBORMembernari:CreditAgreementMembersrt:MaximumMembernari:BankOfAmericaCreditFacilityMembernari:LondonInterbankOfferedRateLoansMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-3100015310482022-01-010001531048us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001531048us-gaap:EmployeeStockMember2022-01-012022-03-310001531048us-gaap:FairValueInputsLevel2Member2022-03-310001531048us-gaap:CommonStockMember2021-01-012021-03-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2021-01-012021-03-310001531048us-gaap:ManufacturingFacilityMember2022-03-310001531048us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001531048us-gaap:AdditionalPaidInCapitalMember2022-03-310001531048us-gaap:ShortTermInvestmentsMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2022-03-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-03-310001531048us-gaap:LetterOfCreditMembernari:BankOfAmericaCreditFacilityMember2022-03-012022-03-310001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandAndElevenEquityIncentivePlanMember2021-01-012021-12-310001531048us-gaap:AdditionalPaidInCapitalMember2021-03-310001531048us-gaap:FairValueInputsLevel1Member2022-03-310001531048us-gaap:LeaseholdImprovementsMember2022-01-012022-03-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2020-09-012020-09-300001531048us-gaap:FairValueInputsLevel1Member2021-12-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2022-01-012022-03-310001531048country:CA2021-01-012021-09-300001531048nari:InceptusMedicalIncMembersrt:MinimumMember2022-01-012022-03-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2021-12-310001531048us-gaap:AdditionalPaidInCapitalMember2020-12-310001531048us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasurySecuritiesMember2022-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2022-03-310001531048us-gaap:FairValueInputsLevel2Membernari:CorporateDebtSecuritiesAndCommercialPaperMember2022-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMembersrt:MaximumMember2020-01-012020-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2020-01-012020-03-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2021-12-310001531048us-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMembersrt:MinimumMember2021-01-012021-03-310001531048us-gaap:FurnitureAndFixturesMember2022-03-310001531048us-gaap:SupplierConcentrationRiskMembersrt:MinimumMembernari:AccountsPayableBenchmarkMember2021-01-012021-12-310001531048us-gaap:OtherLongTermInvestmentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100015310482020-10-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2022-03-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-12-310001531048us-gaap:OtherLongTermInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2021-12-3100015310482022-03-012022-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001531048us-gaap:SalesRevenueNetMembersrt:MinimumMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001531048nari:AccountsReceivableNetMember2022-03-3100015310482021-07-012021-09-300001531048us-gaap:TechnologyEquipmentMember2021-12-310001531048us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-03-310001531048nari:FlowTrieverProductsMember2022-01-012022-03-310001531048nari:EmployeeStockPurchasePlanMember2022-01-012022-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2021-01-012021-03-3100015310482022-01-012022-03-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2021-12-310001531048us-gaap:CostOfSalesMember2022-01-012022-03-310001531048us-gaap:CommonStockMember2021-12-310001531048nari:CreditAgreementMemberus-gaap:FederalFundsEffectiveSwapRateMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-01-012022-03-310001531048srt:MinimumMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-03-310001531048nari:OakCanyonMember2021-12-3100015310482022-01-012022-01-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2020-03-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-03-310001531048us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2022-03-310001531048us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001531048country:CA2019-03-310001531048us-gaap:FairValueInputsLevel3Membernari:CorporateDebtSecuritiesAndCommercialPaperMember2022-03-310001531048us-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMembersrt:MinimumMember2022-01-012022-03-310001531048nari:InceptusMedicalIncMember2022-01-012022-03-3100015310482020-12-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2021-12-310001531048us-gaap:CommonStockMember2022-01-012022-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001531048us-gaap:FairValueInputsLevel3Member2022-03-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2022-01-012022-03-310001531048us-gaap:LetterOfCreditMembernari:BankOfAmericaCreditFacilityMember2021-12-310001531048country:CA2019-03-012019-03-310001531048nari:CorporateDebtSecuritiesAndCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001531048us-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2021-01-012021-03-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2021-01-012021-12-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-3100015310482021-01-012021-03-310001531048us-gaap:EmployeeStockMember2021-01-012021-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001531048us-gaap:RetainedEarningsMember2020-12-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2021-12-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-310001531048us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2021-12-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-310001531048us-gaap:LeaseholdImprovementsMember2021-12-310001531048us-gaap:FairValueInputsLevel1Membernari:CorporateDebtSecuritiesAndCommercialPaperMember2022-03-310001531048nari:ClotTrieverProductsMember2022-01-012022-03-310001531048us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001531048us-gaap:RestrictedStockMember2022-01-012022-03-310001531048us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-03-3100015310482021-01-012021-09-300001531048nari:InceptusMedicalIncMembersrt:MaximumMember2022-01-012022-03-310001531048us-gaap:RetainedEarningsMember2022-03-310001531048us-gaap:OverAllotmentOptionMember2022-03-012022-03-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2022-03-310001531048nari:UnvestedRestrictedStockUnitsMember2021-01-012021-03-310001531048us-gaap:SupplierConcentrationRiskMembernari:AccountsPayableBenchmarkMember2022-01-012022-03-310001531048us-gaap:FurnitureAndFixturesMember2021-12-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2021-12-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:OtherLongTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2021-12-310001531048us-gaap:ShortTermInvestmentsMember2022-03-310001531048us-gaap:CostOfSalesMember2021-01-012021-03-310001531048us-gaap:LondonInterbankOfferedRateLIBORMembernari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-310001531048us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-12-310001531048us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001531048nari:MRITheHoffmanGroupMember2022-03-310001531048us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2022-03-310001531048nari:FlowTrieverProductsMember2021-01-012021-03-310001531048us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-03-310001531048us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001531048us-gaap:RetainedEarningsMember2021-01-012021-03-310001531048us-gaap:ShortTermInvestmentsMember2021-12-310001531048us-gaap:FairValueMeasurementsRecurringMember2021-12-310001531048nari:AccountsReceivableNetMember2021-12-310001531048srt:MaximumMember2022-01-012022-03-310001531048us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001531048country:CA2020-10-012020-10-310001531048nari:CreditAgreementMembersrt:MinimumMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-310001531048us-gaap:IPOMember2021-03-310001531048nari:CorporateDebtSecuritiesAndCommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100015310482021-12-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMember2022-01-012022-03-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2021-01-012021-03-310001531048us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001531048nari:AssetsInProgressMember2021-12-310001531048us-gaap:IPOMember2022-03-312022-03-310001531048us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001531048us-gaap:ResearchAndDevelopmentExpenseMember2022-03-310001531048us-gaap:RestrictedStockUnitsRSUMember2019-03-012019-03-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310001531048nari:ClotTrieverProductsMember2021-01-012021-03-310001531048us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2020-09-300001531048us-gaap:CashAndCashEquivalentsMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2022-03-310001531048us-gaap:SupplierConcentrationRiskMembernari:AccountsPayableBenchmarkMember2021-01-012021-12-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMember2022-03-012022-03-310001531048us-gaap:OtherLongTermInvestmentsMember2021-12-3100015310482021-09-300001531048us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001531048nari:TwoThousandAndElevenEquityIncentivePlanMember2022-01-012022-03-310001531048us-gaap:ComputerEquipmentMember2021-12-3100015310482020-07-012020-09-300001531048us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2021-12-3100015310482022-03-310001531048country:CA2020-10-310001531048us-gaap:ManufacturingFacilityMember2021-12-310001531048nari:UnvestedRestrictedStockUnitsMember2022-01-012022-03-310001531048country:CA2021-09-300001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-05-012020-05-310001531048us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-03-310001531048nari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2021-01-012021-12-310001531048us-gaap:RestrictedStockMember2021-01-012021-03-310001531048us-gaap:CommonStockMember2022-03-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:OtherLongTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2021-12-310001531048nari:RecruitingServicesMembernari:MRITheHoffmanGroupMemberus-gaap:OperatingExpenseMember2021-01-012021-03-310001531048us-gaap:FairValueInputsLevel3Membernari:CorporateDebtSecuritiesAndCommercialPaperMember2021-12-310001531048us-gaap:LetterOfCreditMember2020-10-310001531048us-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2022-01-012022-03-310001531048us-gaap:SupplierConcentrationRiskMembersrt:MinimumMembernari:AccountsPayableBenchmarkMember2022-01-012022-03-310001531048us-gaap:FairValueInputsLevel1Membernari:CorporateDebtSecuritiesAndCommercialPaperMember2021-12-310001531048us-gaap:LeaseholdImprovementsMember2022-03-310001531048us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-03-310001531048nari:TwoThousandTwentyEmployeeStockPurchasePlanMember2020-05-310001531048us-gaap:CommonStockMember2021-03-310001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandAndElevenEquityIncentivePlanMember2022-01-012022-03-310001531048nari:InceptusMedicalIncMember2021-01-012021-03-3100015310482021-03-310001531048nari:CreditAgreementMembersrt:MaximumMembernari:BankOfAmericaCreditFacilityMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-310001531048us-gaap:FairValueInputsLevel2Member2021-12-310001531048us-gaap:LetterOfCreditMembernari:BankOfAmericaCreditFacilityMember2022-03-3100015310482020-10-012020-10-310001531048us-gaap:CommonStockMember2020-12-310001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandAndElevenEquityIncentivePlanMember2021-12-310001531048nari:AssetsInProgressMember2022-03-310001531048us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-310001531048us-gaap:RetainedEarningsMember2022-01-012022-03-310001531048us-gaap:CashAndCashEquivalentsMember2021-12-310001531048us-gaap:FairValueInputsLevel2Membernari:CorporateDebtSecuritiesAndCommercialPaperMember2021-12-310001531048nari:RecruitingServicesMembernari:MRITheHoffmanGroupMemberus-gaap:OperatingExpenseMember2022-01-012022-03-310001531048us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001531048us-gaap:RetainedEarningsMember2021-12-310001531048us-gaap:AdditionalPaidInCapitalMember2021-12-310001531048us-gaap:SalesRevenueNetMembersrt:MinimumMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-3100015310482022-03-312022-03-310001531048nari:MRITheHoffmanGroupMember2021-12-310001531048nari:TwoThousandTwentyIncentiveAwardPlanMembernari:EmployeeStockPurchasePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-01-012022-03-310001531048us-gaap:ShortTermInvestmentsMembernari:CorporateDebtSecuritiesAndCommercialPaperMember2021-12-310001531048us-gaap:ComputerEquipmentMember2022-03-310001531048country:CA2019-03-262019-03-310001531048us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2022-03-310001531048nari:EmployeeStockPurchasePlanMember2021-01-012021-03-310001531048us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-03-310001531048us-gaap:FairValueInputsLevel3Member2021-12-310001531048us-gaap:RestrictedStockUnitsRSUMembernari:TwoThousandAndElevenEquityIncentivePlanMember2022-03-310001531048srt:MaximumMember2019-03-310001531048us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001531048us-gaap:LondonInterbankOfferedRateLIBORMembernari:CreditAgreementMembernari:BankOfAmericaCreditFacilityMembernari:LondonInterbankOfferedRateLoansMembernari:SeniorSecuredRevolvingCreditFacilityMember2022-03-012022-03-310001531048us-gaap:FairValueMeasurementsRecurringMember2022-03-31xbrli:purenari:Vendorxbrli:sharesnari:Customeriso4217:USDxbrli:sharesnari:LetterOfCreditiso4217:USDnari:ExtensionPeriod

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________to ___________

Commission File Number: 001-39293

 

Inari Medical, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

45-2902923

( State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

 

 

6001 Oak Canyon, Suite 100

Irvine, California

92618

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (877) 923-4747

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, $0.001 par value per share

 

NARI

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

As of April 29, 2022, the registrant had 53,125,434 shares of common stock, $0.001 par value per share, outstanding.

 

 


Table of Contents

 

 

 

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

2

 

Condensed Consolidated Statements of Stockholders’ Equity

3

 

Condensed Consolidated Statements of Cash Flows

4

 

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

20

Item 4.

Controls and Procedures

20

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

21

Item 1A.

Risk Factors

21

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

21

Item 3.

Defaults Upon Senior Securities

21

Item 4.

Mine Safety Disclosures

21

Item 5.

Other Information

21

Item 6.

Exhibits

22

Signatures

23

 

i


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,”, “would”, “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report, including without limitation statements regarding our business model and strategic plans for our products, technologies and business, including our implementation thereof, the impact on our business, financial condition and results of operations from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, the timing of and our ability to obtain and maintain regulatory approvals, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the commercial success and market acceptance of our products, the sufficiency of our cash, cash equivalents and short-term investments, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.

The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Quarterly Report entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon these forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

 

 

ii


 

PART I—FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (Unaudited).

Inari Medical, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data and par value)

(unaudited)

 

 

 

March 31,
2022

 

 

December 31,
2021

 

Assets

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

186,556

 

 

$

92,752

 

Short-term investments in debt securities

 

 

152,156

 

 

 

83,348

 

Accounts receivable, net

 

 

44,950

 

 

 

42,351

 

Inventories, net

 

 

23,828

 

 

 

21,053

 

Prepaid expenses and other current assets

 

 

5,849

 

 

 

5,694

 

Total current assets

 

 

413,339

 

 

 

245,198

 

Property and equipment, net

 

 

18,153

 

 

 

16,471

 

Operating lease right-of-use assets

 

 

46,401

 

 

 

44,909

 

Deposits and other assets

 

 

6,216

 

 

 

981

 

Long-term investments in debt securities

 

 

 

 

 

3,983

 

Total assets

 

$

484,109

 

 

$

311,542

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable

 

$

6,066

 

 

$

6,541

 

Payroll-related accruals

 

 

19,729

 

 

 

24,433

 

Accrued expenses and other current liabilities

 

 

9,155

 

 

 

10,737

 

Operating lease liabilities, current portion

 

 

630

 

 

 

802

 

Total current liabilities

 

 

35,580

 

 

 

42,513

 

Operating lease liabilities, noncurrent portion

 

 

28,301

 

 

 

28,404

 

Other long-term liability

 

 

1,416

 

 

 

1,416

 

Total liabilities

 

 

65,297

 

 

 

72,333

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares
   issued and outstanding as of March 31, 2022 and December 31, 2021

 

 

 

 

 

 

Common stock, $0.001 par value, 300,000,000 shares
   authorized as of March 31, 2022 and December 31, 2021;
53,022,905 
   and
50,313,452 shares issued and outstanding as of March 31, 2022 and
   December 31, 2021, respectively

 

 

53

 

 

 

50

 

Additional paid in capital

 

 

440,238

 

 

 

257,144

 

Accumulated other comprehensive loss

 

 

(767

)

 

 

(402

)

Accumulated deficit

 

 

(20,712

)

 

 

(17,583

)

Total stockholders' equity

 

 

418,812

 

 

 

239,209

 

Total liabilities and stockholders' equity

 

$

484,109

 

 

$

311,542

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1


 

Inari Medical, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Revenue

 

$

86,752

 

 

$

57,397

 

Cost of goods sold

 

 

9,967

 

 

 

4,623

 

Gross profit

 

 

76,785

 

 

 

52,774

 

Operating expenses

 

 

 

 

 

 

Research and development

 

 

16,135

 

 

 

8,163

 

Selling, general and administrative

 

 

63,732

 

 

 

36,898

 

Total operating expenses

 

 

79,867

 

 

 

45,061

 

(Loss) income from operations

 

 

(3,082

)

 

 

7,713

 

Other income (expense)

 

 

 

 

 

 

Interest income

 

 

50

 

 

 

68

 

Interest expense

 

 

(73

)

 

 

(73

)

Other expenses

 

 

(24

)

 

 

(41

)

Total other expenses

 

 

(47

)

 

 

(46

)

(Loss) income before income taxes

 

 

(3,129

)

 

 

7,667

 

Provision for income taxes

 

 

 

 

 

198

 

Net (loss) income

 

$

(3,129

)

 

$

7,469

 

Other comprehensive income (loss)

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

(117

)

 

 

(180

)

Unrealized (loss) gain on available-for-sale debt securities

 

 

(248

)

 

 

18

 

Total other comprehensive loss

 

 

(365

)

 

 

(162

)

Comprehensive (loss) income

 

$

(3,494

)

 

$

7,307

 

Net (loss) income per share

 

 

 

 

 

 

Basic

 

$

(0.06

)

 

$

0.15

 

Diluted

 

$

(0.06

)

 

$

0.13

 

Weighted average common shares used to compute net
       (loss) income per share

 

 

 

 

 

 

Basic

 

 

50,954,715

 

 

 

49,355,945

 

Diluted

 

 

50,954,715

 

 

 

55,722,293

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2


 

Inari Medical, Inc.

Condensed Consolidated Statements Stockholders’ Equity

(in thousands, except share data)

(unaudited)

 

 

 

Common Stock

 

 

Additional Paid In

 

 

Accumulated Other Comprehensive

 

 

Accumulated

 

 

Total
Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance, December 31, 2021

 

 

50,313,452

 

 

$

50

 

 

$

257,144

 

 

$

(402

)

 

$

(17,583

)

 

$

239,209

 

Options exercised for
  common stock

 

 

322,882

 

 

 

1

 

 

 

344

 

 

 

 

 

 

 

 

 

345

 

Shares issued under Employee
  Stock Purchase Plan

 

 

54,808

 

 

 

 

 

 

3,427

 

 

 

 

 

 

 

 

 

3,427

 

Issuance of common stock upon
  vesting of restricted stock units,
  net of shares withheld for taxes

 

 

31,763

 

 

 

 

 

 

(1,624

)

 

 

 

 

 

 

 

 

(1,624

)

Issuance of common stock in
  public offering, net of
  issuance costs of $
11.9 million

 

 

2,300,000

 

 

 

2

 

 

 

174,392

 

 

 

 

 

 

 

 

 

174,394

 

Share-based compensation
  expense

 

 

 

 

 

 

 

 

6,555

 

 

 

 

 

 

 

 

 

6,555

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(365

)

 

 

 

 

 

(365

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,129

)

 

 

(3,129

)

Balance, March 31, 2022

 

 

53,022,905

 

 

$

53

 

 

$

440,238

 

 

$

(767

)

 

$

(20,712

)

 

$

418,812

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2020

 

 

49,251,614

 

 

$

49

 

 

$

227,624

 

 

$

4

 

 

$

(27,423

)

 

$

200,254

 

Options exercised for
  common stock

 

 

296,019

 

 

 

1

 

 

 

380

 

 

 

 

 

 

 

 

 

381

 

Shares issued under Employee
  Stock Purchase Plan

 

 

36,881

 

 

 

 

 

 

1,882

 

 

 

 

 

 

 

 

 

1,882

 

Issuance of common stock upon
  vesting of restricted stock units,
  net of shares withheld for taxes

 

 

901

 

 

 

 

 

 

(49

)

 

 

 

 

 

 

 

 

(49

)

Share-based compensation
  expense

 

 

 

 

 

 

 

 

3,836

 

 

 

 

 

 

 

 

 

3,836

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(162

)

 

 

 

 

 

(162

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7,469

 

 

 

7,469

 

Balance, March 31, 2021

 

 

49,585,415

 

 

$

50

 

 

$

233,673

 

 

$

(158

)

 

$

(19,954

)

 

$

213,611

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3


 

Inari Medical, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities

 

 

 

 

 

 

Net (loss) income

 

$

(3,129

)

 

$

7,469

 

Adjustments to reconcile net (loss) income to net cash (used in) provided by
  operating activities:

 

 

 

 

 

 

Depreciation

 

 

1,063

 

 

 

609

 

Amortization of deferred financing costs

 

 

36

 

 

 

36

 

Amortization of right-of-use assets

 

 

604

 

 

 

177

 

Share-based compensation expense

 

 

6,555

 

 

 

3,836

 

Allowance for credit losses

 

 

79

 

 

 

139

 

Changes in:

 

 

 

 

 

 

Accounts receivable

 

 

(2,695

)

 

 

(3,437

)

Inventories

 

 

(2,788

)

 

 

(3,073

)

Prepaid expenses, deposits and other assets

 

 

261

 

 

 

(2,908

)

Accounts payable

 

 

(467

)

 

 

2,473

 

Payroll-related accruals, accrued expenses and other liabilities

 

 

(6,247

)

 

 

3,635

 

Lease prepayments for lessor's owned leasehold improvements

 

 

(2,097

)

 

 

 

Operating lease liabilities

 

 

(275

)

 

 

(190

)

Net cash (used in) provided by operating activities

 

 

(9,100

)

 

 

8,766

 

Cash flows from investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

(2,745

)

 

 

(1,265

)

Purchases of marketable securities

 

 

(112,073

)

 

 

(21,246

)

Purchases of other investments

 

 

(5,693

)

 

 

 

Maturities of marketable securities

 

 

47,000

 

 

 

 

Net cash used in investing activities

 

 

(73,511

)

 

 

(22,511

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from issuance of common stock in public offering, net of
   issuance costs of $
11.9 million

 

 

174,394

 

 

 

 

Proceeds from issuance of common stock under employee stock purchase plan

 

 

3,427

 

 

 

1,882

 

Proceeds from exercise of stock options

 

 

345

 

 

 

381

 

Payment of taxes related to vested restricted stock units

 

 

(1,624

)

 

 

(49

)

Net cash provided by financing activities

 

 

176,542

 

 

 

2,214

 

Effect of foreign exchange rate on cash and cash equivalents

 

 

(127

)

 

 

(183

)

Net increase (decrease) in cash

 

 

93,804

 

 

 

(11,714

)

Cash and cash equivalents beginning of period

 

 

92,752

 

 

 

114,617

 

Cash and cash equivalents end of period

 

$

186,556

 

 

$

102,903

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

Cash paid for income taxes

 

$

89

 

 

$

118

 

Cash paid for interest

 

$

37

 

 

$

37

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4


Inari Medical, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

1. Organization

Description of Business

Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company develops, manufactures, markets and sells devices for the interventional treatment of venous diseases.

2. Summary of Significant Accounting Policies

COVID-19

The global healthcare system continues to face an unprecedented challenge as a result of the novel coronavirus, or COVID-19, situation and its impact. COVID-19 is having, and may continue to have, an adverse impact on significant aspects of the Company and the business, including the demand for products, business operations, and the ability to research and develop and bring to market new products and services. To the extent individuals and hospital systems de-prioritize, delay or cancel deferrable medical procedures as a result of COVID-19, staffing or resource issues, or otherwise, the Company’s business, cash flows, financial condition and results of operations may continue to be negatively affected.

The Company continues to focus its efforts on the health and safety of patients, healthcare providers and employees, while executing its mission of transforming lives of venous thromboembolism ("VTE") patients. However, the Company expects the COVID-19 pandemic may continue to negatively impact 2022 performance.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

The interim condensed consolidated balance sheet as of March 31, 2022, the condensed consolidated statements of operations and comprehensive income (loss), stockholders’ equity, and cash flows for the three months ended March 31, 2022 and 2021 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s consolidated financial position as of March 31, 2022 and its consolidated results of operations and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in the notes to the condensed consolidated financial statements related to the three months ended March 31, 2022 and 2021 are also unaudited. The condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed on February 23, 2022.

Principles of Consolidation

The condensed consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Management Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements may include, but are not limited to, collectability of receivables, recoverability of long-lived assets, valuation of inventory, other investments, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.

Revenue Recognition

5


Inari Medical, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

The Company sells its products primarily to hospitals in the United States utilizing the Company’s direct sales force. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representative hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, administrative fees and sales rebates.

Performance Obligation—The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product.

Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s consolidated financial statements.

As of March 31, 2022 and December 31, 2021, the Company recorded $630,000 and $448,000, respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying consolidated balance sheets.

Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow:

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

ClotTriever

 

 

32

%

 

 

35

%

FlowTriever

 

 

68

%

 

 

65

%

 

The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price.

The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold.

Costs associated with product sales include commissions and are recorded in selling, general and administrative ("SG&A") expenses. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period is less than one year.

Other Investments

In March 2022, the Company made investments in certain privately held companies, with no readily determinable fair value. The Company measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investments. The Company will monitor the information that becomes available from time to time and adjust the carrying values of these investments if there are identified events or changes in circumstances that have a significant adverse effect on the fair values. As of March 31, 2022, total other investments of $5.7 million was included in deposits and other assets on the condensed consolidated balance sheets.

6


Inari Medical, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

3. Fair Value Measurements

The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of March 31, 2022 and December 31, 2021 (in thousands):

 

 

 

March 31, 2022

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Aggregate Fair Value

 

Financial Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market mutual funds

 

$

87,969

 

 

$

 

 

$

 

 

$

87,969

 

U.S. Treasury securities

 

 

26,101

 

 

 

 

 

 

 

 

 

26,101

 

Corporate debt securities and commercial paper

 

 

 

 

 

6,491

 

 

 

 

 

 

6,491

 

Total included in cash and cash equivalents

 

 

114,070

 

 

 

6,491

 

 

 

 

 

 

120,561

 

Investments:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

95,386

 

 

 

 

 

 

 

 

 

95,386

 

U.S. Government agencies

 

 

 

 

 

5,997

 

 

 

 

 

 

5,997

 

Corporate debt securities and commercial paper

 

 

 

 

 

50,773

 

 

 

 

 

 

50,773

 

Total included in short-term investments

 

 

95,386

 

 

 

56,770

 

 

 

 

 

 

152,156

 

Total assets

 

$

209,456

 

 

$

63,261

 

 

$

 

 

$

272,717

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Aggregate Fair Value

 

Financial Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market mutual funds

 

$

48,595

 

 

$

 

 

$

 

 

$

48,595